newsfilter
← Latest News
GlobeNewswire·

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% versus Q1 of 2026, driven primarily by strong demand growthCompany raising 2026